Drug Trial Radar · NCT01523587
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Last checked: Nov 19, 2026Latest source record: Feb 15, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
795
Actual
Start
Mar 5, 2012
Primary completion
Oct 21, 2013
Study completion Dec 27, 2017
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 1, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomised, open-label phase III trial will be performed in patients with advanced squamous cell carcinoma of the lung requiring second-line treatment after receiving first-line platinum-based chemotherapy. The primary objective of this trial is to compare the efficacy of BIBW 2992 to erlotinib as second-line treatment in this group of patients.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
afatinibDrug
Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
erlotinibDrug
erlotinib taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1Time frame: First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).
Locations
192 sites in 23 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona
University of California
La Jolla, California
Sutter Medical Group
Sacramento, California
Boca Raton Reginl Hospital-Lynn Cancer Institute
Boca Raton, Florida
Memorial Healthcare System
Hollywood, Florida
Cancer Care of North Florida, PA
Lake City, Florida
Illinois Cancer Specialists
Niles, Illinois
Orchard Healthcare Research Inc
Skokie, Illinois
University of Louisville
Louisville, Kentucky
West Jefferson General Hospital and Cancer Clinic
Marrero, Louisiana
Lahey Clinic
Burlington, Massachusetts
Commonwealth Hematology-Oncology, PC
Lawrence, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
Washington University School of Medicine
St Louis, Missouri
Billings Clinic Cancer Center
Billings, Montana
Queens Medical Associates
Fresh Meadows, New York
SUNY Upstate Medical University
Syracuse, New York
Montefiore Medical Center
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Cleveland Clinic
Cleveland, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Mid Ohio Oncology/Hematology, Inc
Columbus, Ohio
Kaiser Permanente Northwest
Portland, Oregon
Oncology Hematology Associates of Norhtern Pennsylvania, PC
DuBois, Pennsylvania
Kimmel Cancer Center
Philadelphia, Pennsylvania
Temple University Cancer Center
Philadelphia, Pennsylvania
Spartanburg Regional Medical Center
Spartanburg, South Carolina
Cancer Center of Cookeville Regional Medical Center
Cookeville, Tennessee
Paris Cancer Center (PCC), Texas Oncology
Paris, Texas
Cancer Therapy and Research at UTHSCSA
San Antonio, Texas
Fletcher Allen Health Care
Burlington, Vermont
Blue Ridge Cancer Care
Christiansburg, Virginia
Virginia Oncology Associates
Norfolk, Virginia
Instituto Medico Especializado Alexander Fleming
Ciudad Autonoma de Bs As, Argentina
Instituto Oncologico de Cordoba
Córdoba, Argentina
Clínica Colombo S.A.
Córdoba, Argentina
Centro Oncologico de Rosario
Rosario, Argentina
Centro Oncologico CAIPO
San Miguel de Tucumán, Argentina
Medical University of Innsbruck
Innsbruck, Austria
LKH Leoben
Leoben, Austria
Showing 40 of 192 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.